This article has Open Peer Review reports available.
Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
© The Author(s). 2018
Received: 31 December 2016
Accepted: 30 October 2017
Published: 3 January 2018
Open Peer Review reports
Pre-publication versions of this article and author comments to reviewers are available by contacting firstname.lastname@example.org.
|31 Dec 2016||Submitted||Original manuscript|
|22 Feb 2017||Reviewed||Reviewer Report - Herbert Loong|
|28 Feb 2017||Reviewed||Reviewer Report - Christine Fillmore Brainson|
|9 Jul 2017||Author responded||Author comments - Jianya Zhou|
|Resubmission - Version 2|
|9 Jul 2017||Submitted||Manuscript version 2|
|14 Sep 2017||Reviewed||Reviewer Report - Herbert Loong|
|8 Oct 2017||Author responded||Author comments - Jianya Zhou|
|Resubmission - Version 3|
|8 Oct 2017||Submitted||Manuscript version 3|
|30 Oct 2017||Editorially accepted|
|3 Jan 2018||Article published||10.1186/s12885-017-3720-8|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting email@example.com. All previous versions of the manuscript and all author responses to the reviewers are also available.
You can find further information about the peer review system here.